Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment

Dow Jones12-12 21:46

By Connor Hart

Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility.

The study, which was being conducted in partnership with Gilead Sciences, aimed to evaluate STAR-221 as a first-line treatment for advanced gastric and esophageal cancers.

The biopharmaceutical company said Friday that an interim analysis of results showed that STAR-221 didn't improve overall survival relative to existing treatment options. The safety profile for the treatment was similar to that of existing options, and no new safety findings were identified, it added.

The decision to end the trial was based on the recommendation of an independent data monitoring committee. Arcus and Gilead said they are communicating with investigators to determine appropriate next steps for patients in the study, in addition to conducting a detailed analysis to better understand the results.

"We are disappointed with this outcome and sincerely thank all those who participated in the study and made this research possible," said Arcus Chief Medical Officer Richard Markus. "We remain committed to advancing research for people living with cancer and immune-related diseases."

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

December 12, 2025 08:46 ET (13:46 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590796501?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590796501","market":"nz","top_or_hot":-1,"title":"Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences</a> said it will discontinue a late-stage trial for its potential cancer treatment due to futility. \n</p>\n<p>\n  The study, which was being conducted in partnership with <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences, aimed to evaluate STAR-221 as a first-line treatment for advanced gastric and esophageal cancers. \n</p>\n<p>\n  The biopharmaceutical company said Friday that an interim analysis of results showed that STAR-221 didn't improve overall survival relative to existing treatment options. The safety profile for the treatment was similar to that of existing options, and no new safety findings were identified, it added. \n</p>\n<p>\n  The decision to end the trial was based on the recommendation of an independent data monitoring committee. Arcus and Gilead said they are communicating with investigators to determine appropriate next steps for patients in the study, in addition to conducting a detailed analysis to better understand the results. \n</p>\n<p>\n  \"We are disappointed with this outcome and sincerely thank all those who participated in the study and made this research possible,\" said Arcus Chief Medical Officer Richard Markus. \"We remain committed to advancing research for people living with cancer and immune-related diseases.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2025 08:46 ET (13:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-12 21:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences</a> said it will discontinue a late-stage trial for its potential cancer treatment due to futility. \n</p>\n<p>\n  The study, which was being conducted in partnership with <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences, aimed to evaluate STAR-221 as a first-line treatment for advanced gastric and esophageal cancers. \n</p>\n<p>\n  The biopharmaceutical company said Friday that an interim analysis of results showed that STAR-221 didn't improve overall survival relative to existing treatment options. The safety profile for the treatment was similar to that of existing options, and no new safety findings were identified, it added. \n</p>\n<p>\n  The decision to end the trial was based on the recommendation of an independent data monitoring committee. Arcus and Gilead said they are communicating with investigators to determine appropriate next steps for patients in the study, in addition to conducting a detailed analysis to better understand the results. \n</p>\n<p>\n  \"We are disappointed with this outcome and sincerely thank all those who participated in the study and made this research possible,\" said Arcus Chief Medical Officer Richard Markus. \"We remain committed to advancing research for people living with cancer and immune-related diseases.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2025 08:46 ET (13:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2087621335.USD","symbol_name":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590796501","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590796501","pubTimestamp":1765547160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility.The study, which was being conducted in partnership with Gilead Sciences, aimed to evaluate STAR-221 as a first-line treatment for advanced gastric and esophageal cancers.The biopharmaceutical company said Friday that an interim analysis of results showed that STAR-221 didn't improve overall survival relative to existing treatment options. The safety profile for the treatment was similar to that of existing options, and no new safety findings were identified, it added.The decision to end the trial was based on the recommendation of an independent data monitoring committee. Arcus and Gilead said they are communicating with investigators to determine appropriate next steps for patients in the study, in addition to conducting a detailed analysis to better understand the results.\"We are disappointed with this outcome and sincerely thank all those who participated in the study an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","GILD":"吉利德科学","RCUS":"Arcus Biosciences Inc.","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4139":"生物科技","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4566":"资本集团","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4578":"CAR-T","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4568":"美国抗疫概念","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","BK4550":"红杉资本持仓","BK4588":"碎股","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4583":"猴痘概念","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4532":"文艺复兴科技持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"translate_title":"Arcus Biosciences将停止潜在癌症治疗的3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCUS":0.9,"GILD":0.9},"content_text":"By Connor Hart \n\n\n \n\n\nArcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. \n\n\n  The study, which was being conducted in partnership with Gilead Sciences, aimed to evaluate STAR-221 as a first-line treatment for advanced gastric and esophageal cancers. \n\n\n  The biopharmaceutical company said Friday that an interim analysis of results showed that STAR-221 didn't improve overall survival relative to existing treatment options. The safety profile for the treatment was similar to that of existing options, and no new safety findings were identified, it added. \n\n\n  The decision to end the trial was based on the recommendation of an independent data monitoring committee. Arcus and Gilead said they are communicating with investigators to determine appropriate next steps for patients in the study, in addition to conducting a detailed analysis to better understand the results. \n\n\n  \"We are disappointed with this outcome and sincerely thank all those who participated in the study and made this research possible,\" said Arcus Chief Medical Officer Richard Markus. \"We remain committed to advancing research for people living with cancer and immune-related diseases.\" \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 08:46 ET (13:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590796501","isCrawlerRequest":true}